Health Advisory:
Outbreak of Hepatitis A Virus (HAV) Infections among Persons Who Use Drugs and Persons Experiencing Homelessness

June 14, 2018

This document will be updated as new information becomes available. The current version can always be viewed at http://www.health.mo.gov.

The Missouri Department of Health & Senior Services (DHSS) is now using 4 types of documents to provide important information to medical and public health professionals, and to other interested persons:

Health Alerts convey information of the highest level of importance which warrants immediate action or attention from Missouri health providers, emergency responders, public health agencies, and/or the public.

Health Advisories provide important information for a specific incident or situation, including that impacting neighboring states; may not require immediate action.

Health Guidances contain comprehensive information pertaining to a particular disease or condition, and include recommendations, guidelines, etc. endorsed by DHSS.

Health Updates provide new or updated information on an incident or situation; can also provide information to update a previously sent Health Alert, Health Advisory, or Health Guidance; unlikely to require immediate action.

Office of the Director
912 Wildwood
P.O. Box 570
Jefferson City, MO 65102
Telephone: 800-392-0272
Fax: 573-751-6041
Website: http://www.health.mo.gov

FROM: RANDALL W. WILLIAMS, MD, FACOG
DIRECTOR

SUBJECT: Outbreak of Hepatitis A Virus (HAV) Infections Among Persons Who Use Drugs and Persons Experiencing Homelessness

Summary
The Missouri Department of Health and Senior Services (DHSS) in collaboration with several local public health agencies is currently monitoring and responding to a hepatitis A outbreak in Southeast Missouri. From September 1, 2017 to June 13, 2018, 127 confirmed cases of hepatitis A virus infection have been linked to this ongoing outbreak. This Health Advisory alerts local public health agencies (LPHAs), healthcare facilities, and programs providing services to affected populations about these outbreaks of hepatitis A infections and provides guidance to assist in identifying and preventing new infections.*

Background
Hepatitis A infection is a vaccine-preventable illness. The primary means of hepatitis A virus (HAV) transmission in the United States is typically person-to-person through the fecal-oral route (i.e., ingestion of something that has been contaminated with the feces of an infected person).1 Symptoms include fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, clay-colored bowel movements, joint pain, and jaundice. Although rare, atypical extra hepatic manifestations include rash, pancreatitis, renal disease, arthritis, and anemia.2 Severe infections can result in cholestatic hepatitis, relapsing hepatitis, and fulminant hepatitis leading to death.3 Average incubation of HAV is 28 days, but illness can occur up to 50 days after exposure.4 An HAV-infected person can be viremic up to six weeks through their clinical course and excrete virus in stool for up to two weeks prior to becoming symptomatic, making identifying exposures particularly difficult.5-7 Illness from hepatitis A is typically acute and self-limited; however, when this disease affects populations with already poor health (e.g., hepatitis B and C infections, chronic liver disease), infection can lead to serious outcomes, including death.

The best way to prevent hepatitis A infection is through vaccination with the hepatitis A vaccine. The number and timing of the doses depends on the type of vaccine administered. Vaccines containing HAV antigen that are currently licensed in the United States are the single-antigen vaccines HAVRIX® (manufactured by GlaxoSmithKline) and VAQTA® (manufactured by Merck & Co., Inc.) and the combination vaccine TWINRIX® (containing both HAV and hepatitis B virus antigens; manufactured by GlaxoSmithKline). All are inactivated vaccines. GamaSTAN S/D (Grifols Therapeutics, Inc.) immune globulin (IG) for intramuscular administration is the only IG product approved for HAV prophylaxis. The efficacy of IG or vaccine when administered >2 weeks after exposure has not been established. Additionally, practicing good hand hygiene—including thoroughly washing hands

*Much of the content in this DHSS Health Advisory was taken from a June 11, 2018, Health Advisory from the Centers for Disease Control and Prevention (CDC). However, the CDC recommendations were modified to correspond to DHSS’ current recommendations for Missouri.
after using the bathroom, changing diapers, and before preparing or eating food—plays an important role in preventing the spread of hepatitis A.

From January 2017 to April 2018, the Centers for Disease Control and Prevention (CDC) has received more than 2,500 reports of hepatitis A infections associated with person-to-person transmission from multiple states. Of the more than 1,900 reports for which risk factors are known, more than 1,300 (68%) of the infected persons report drug use (injection and non-injection), homelessness, or both. During this time, responses conducted in various states resulted in increased vaccine demand and usage, resulting in constrained supplies of vaccine. As available vaccine supply has increased and progress has been made towards controlling ongoing outbreaks in some jurisdictions, vaccine is more readily available. However, both CDC and vaccine manufacturers continue to closely monitor ongoing demand for adult hepatitis A vaccine in the United States.

During the mid-1980s, drug use was a risk factor for >20% of all hepatitis A cases reported to CDC, but no large outbreaks have occurred among persons who use drugs since adoption of the recommendation for hepatitis A vaccination of persons who use injection and non-injection drugs was made in 1996. Outbreaks of hepatitis A infections among homeless persons have occurred in other countries, but large outbreaks among the homeless have not been described previously in the United States.

Person-to-person transmission of HAV between persons who report drug use and/or homelessness could result from contaminated needles and other injection paraphernalia, specific sexual contact and practices, or from generally poor sanitary conditions. Transience, economic instability, limited access to healthcare, distrust of public officials and public messages, and frequent lack of follow-up contact information makes this population difficult to reach for preventive services such as vaccination, use of sterile injection equipment, and case management and contact tracing. These challenges make outbreaks among these groups difficult to control.

Rapid identification, a comprehensive response, and novel public health approaches may be required to address needs unique to these populations. Urgent action is needed to prevent further HAV transmission among these risk groups.

Recommendations for LPHAs

1. Ensure standard operating procedures to identify and interview cases, perform contact tracing for all new hepatitis A diagnoses, and provide post-exposure vaccination of contacts as soon as the diagnosis is made.

2. Remind venues that may encounter undiagnosed infections, such as emergency departments and community-based clinical practices (e.g., family medicine, general medicine) of the importance of reporting hepatitis A infections to the LPHA.

3. LPHAs should notify their state health department of any suspected clusters of acute hepatitis A.

Recommendations for Health Care Providers

1. Consider hepatitis A as a diagnosis in anyone with jaundice and clinically compatible symptoms.

2. Encourage persons who have been exposed recently to HAV and who have not been vaccinated to be administered one dose of single-antigen hepatitis A vaccine or immune globulin (IG) as soon as possible, within 2 weeks after exposure. Guidelines vary by age and health status (please see https://www.cdc.gov/hepatitis/outbreaks/InterimOutbreakGuidance-HAV-VaccineAdmin.htm for additional information).
3. Ensure all persons diagnosed with hepatitis A are reported to the health department in a timely manner.

4. Encourage hepatitis A vaccination for persons who report drug use or other risk factors for hepatitis A.

5. CDC recommends the following groups be vaccinated against hepatitis A:
   - All children at age 1 year
   - Persons who are at increased risk for infection:
     - Persons traveling to or working in countries that have high or intermediate endemicity of hepatitis A;
     - Men who have sex with men;
     - Persons who use injection and non-injection drugs;
     - Persons who have occupational risk for infection;
     - Persons who have chronic liver disease;
     - Persons who have clotting-factor disorders;
     - Household members and other close personal contacts or adopted children newly arriving from countries with high or intermediate hepatitis A endemicity; and
     - Persons with direct contact with persons who have hepatitis A.
   - Persons who are at increased risk for complications from hepatitis A, including people with chronic liver diseases, such as hepatitis B or hepatitis C.
   - Any person wishing to obtain immunity.

**For More Information**

Questions should be directed to DHSS’ Bureau of Communicable Disease Control and Prevention at 573-751-6113 or 800-392-0272 (24/7). For additional information, see:


References
1. Purcell RH, Wong DC, Shapiro M. Relative infectivity of hepatitis A virus by the oral and intravenous 
2. Lemon SM, Ott JJ, Van Damme P, Shouval D. Type A viral hepatitis: A summary and update on the 
   in volunteers bearing on immunological and other characteristics of the etiological agents. Am J Med 
   1946; 1: 3-22.
7. Lanford RE, Feng Z, Chavez D, et al. Acute hepatitis A virus infection is associated with a limited type I 
   11223-8.
8. California Department of Public Health. Hepatitis A Outbreak in California 
   https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/Immunization/Hepatitis-A-Outbreak.aspx
   https://chfs.ky.gov/agencies/dph/dehp/Documents/Acute%20Hepatitis%20A%20Outbreak%20Week%20 
   21%20Report.pdf
    Summary. 
    https://www.michigan.gov/documents/mdhhs/HepA_Summ_County_SEMI2016_updated91517_60155 
    2_7.pdf


